{"entity":{"id":"nct01331239","kind":"trial","name":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","aka":[],"tldr":"A phase 2 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","summary":"Safety and Efficacy of LCI699 in Cushing's Disease Patients is a phase 2 interventional study registered as NCT01331239 by Novartis Pharmaceuticals, with 31 participants recorded, started 2011-03-23 and reaching its primary completion in 2019-10-22. Interventions recorded: LCI699. Conditions recorded: Cushings Disease, Cushing Disease.\n\nLinked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01331239","url":"https://clinicaltrials.gov/study/NCT01331239"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["osilodrostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01331239","phase":"2","setting":"A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease","sponsor":"Novartis Pharmaceuticals","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01331239/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/"}]}}